- Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
- Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
- Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
- Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
- Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
As of last trade
Arrowhead Pharmaceuticals Inc (A2RR34:SAO) traded at 18.54, 3.92% above its 52-week low of 17.84, set on Jun 13, 2022.
17.84Jun 13 202230.33Aug 12 2022
Short selling activityProvided by S&P Global Market Intelligence
Data delayed at least 15 minutes, as of Mar 09 2023.